Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$3.08M, compared with -$4.16M a year earlier.

Context

  • Net debt amounted to 87.9% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
  • Net debt increased in 0 of the last 2 fiscal years.
  • FY2025 was the lowest annual figure in the 3 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +26.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.08M+40.1% QoQ
Last fiscal yearDec 2025
-$5.14M-11.3% YoY
Year agoMar 2025
-$4.16M+26.0% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.0%——
1 year-11.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(5.14M) USD
Year-over-year change
-11.3%

Net Debt vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's Mar 2026 net debt of -$3.08M is the 2nd highest of the 8 companies compared; the peer median is -$46.92M.
  • Its year-over-year change of +26.0% is the 4th highest of 8, against a peer median of -23.9%.
  • Net debt amounts to 87.9% of total assets for PLYX, versus a peer median of 21.1%.
PLYX Competitors Peer median
Net Debt for PLYX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTHSPelthos Therapeutics Inc.Mar 2026$20.71M +772.9%+225.9%14.2%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026-$3.08M +26.0%—87.9%
KLRSKalaris Therapeutics IncMar 2026-$33.02M +67.3%—30.1%
LYELLyell Immunopharma, Inc.Mar 2026-$41.92M +33.7%—12.0%
FHTXFoghorn Therapeutics Inc.Mar 2026-$46.92M -79.3%—21.1%
ANTXAN2 Therapeutics, Inc.Mar 2026-$53.49M -167.6%—61.1%
JBIOJade Biosciences, Inc.Mar 2026-$54.41M -23.9%—17.0%
CBIOCrescent Biopharma, Inc.Mar 2026-$187.62M -3241.9%—94.2%
Peer median (excluding PLYX) -$46.92M-23.9%+225.9%21.1%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.